Julieta Leone1, Rachel A Freedman2,3, Nancy U Lin2,3, Sara M Tolaney2,3, Carlos T Vallejo1, Bernardo A Leone1, Eric P Winer2,3, José Pablo Leone4,5. 1. Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. 3. Harvard Medical School, Boston, MA, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. josep_leone@dfci.harvard.edu. 5. Harvard Medical School, Boston, MA, USA. josep_leone@dfci.harvard.edu.
Abstract
PURPOSE: Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear. METHODS: Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS. RESULTS: We included 2389 men with a median follow-up of 43 months (IQR 19-68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2-, 12.7% HR+/HER2+ , 0.8% HR-/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2-, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (p < 0.0001). Of all subtypes, TN had the worst BCSS (p < 0.0001). Stage, tumor subtype and race were significantly associated with OS and BCSS in multivariate analysis. Adjusted Cox hazard ratios for OS by tumor subtype with HR+/HER2- as reference were 1.55 for HR+/HER2+ (p = 0.001), 1.1 for HR-/HER2+ (p = 0.888), and 3.59 for TN (p < 0.001). CONCLUSION: We observed significant differences in survival outcomes by tumor subtype. Poor outcomes among men with HER2+ and TN disease suggest possible under-treatment, aggressive tumor biology, and/or more advanced disease at presentation. Studies to better understand the inferior survival for men with these subtypes are warranted and will likely require international collaboration.
PURPOSE:Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear. METHODS: Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS. RESULTS: We included 2389 men with a median follow-up of 43 months (IQR 19-68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2-, 12.7% HR+/HER2+ , 0.8% HR-/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2-, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (p < 0.0001). Of all subtypes, TN had the worst BCSS (p < 0.0001). Stage, tumor subtype and race were significantly associated with OS and BCSS in multivariate analysis. Adjusted Cox hazard ratios for OS by tumor subtype with HR+/HER2- as reference were 1.55 for HR+/HER2+ (p = 0.001), 1.1 for HR-/HER2+ (p = 0.888), and 3.59 for TN (p < 0.001). CONCLUSION: We observed significant differences in survival outcomes by tumor subtype. Poor outcomes among men with HER2+ and TN disease suggest possible under-treatment, aggressive tumor biology, and/or more advanced disease at presentation. Studies to better understand the inferior survival for men with these subtypes are warranted and will likely require international collaboration.
Authors: Marijn A Vermeulen; Leen Slaets; Fatima Cardoso; Sharon H Giordano; Konstantinos Tryfonidis; Paul J van Diest; Nizet H Dijkstra; Carolien P Schröder; Christi J van Asperen; Barbro Linderholm; Kim Benstead; Renee Foekens; John W M Martens; John M S Bartlett; Carolien H M van Deurzen Journal: Eur J Cancer Date: 2017-03-11 Impact factor: 9.162
Authors: José Pablo Leone; Julieta Leone; Ariel Osvaldo Zwenger; Julián Iturbe; Carlos Teodoro Vallejo; Bernardo Amadeo Leone Journal: Breast Cancer Res Treat Date: 2015-07-01 Impact factor: 4.872
Authors: F Cardoso; J M S Bartlett; L Slaets; C H M van Deurzen; E van Leeuwen-Stok; P Porter; B Linderholm; I Hedenfalk; C Schröder; J Martens; J Bayani; C van Asperen; M Murray; C Hudis; L Middleton; J Vermeij; K Punie; J Fraser; M Nowaczyk; I T Rubio; S Aebi; C Kelly; K J Ruddy; E Winer; C Nilsson; L Dal Lago; L Korde; K Benstead; O Bogler; T Goulioti; A Peric; S Litière; K C Aalders; C Poncet; K Tryfonidis; S H Giordano Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Abeer M Shaaban; Graham R Ball; Rebecca A Brannan; Gabor Cserni; Anna Di Benedetto; Jo Dent; Laura Fulford; Helen Honarpisheh; Lee Jordan; J Louise Jones; Rani Kanthan; Loaie Maraqa; Maria Litwiniuk; Marcella Mottolese; Steven Pollock; Elena Provenzano; Philip R Quinlan; Georgina Reall; Sami Shousha; Mark Stephens; Eldo T Verghese; Rosemary A Walker; Andrew M Hanby; Valerie Speirs Journal: Breast Cancer Res Treat Date: 2011-11-18 Impact factor: 4.872
Authors: Mariana Chavez-Macgregor; Christina A Clarke; Daphne Lichtensztajn; Gabriel N Hortobagyi; Sharon H Giordano Journal: Cancer Date: 2013-01-22 Impact factor: 6.860
Authors: Suleiman Alfred Massarweh; George W Sledge; Dave P Miller; Debbie McCullough; Valentina I Petkov; Steven Shak Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: Yimin Ge; Nour Sneige; Mahmoud A Eltorky; Zhiqin Wang; E Lin; Yun Gong; Ming Guo Journal: Breast Cancer Res Date: 2009-05-14 Impact factor: 6.466